LAVA THERAPEUTICS N.V.

Analyst Reco. LAVA Therapeutics N.V.

Equities

LVTX

NL0015000AG6

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
2.64 ^USD	-3.65%		-6.71%	+67.09%

Mar. 20	LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 20	LAVA Therapeutics N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Price Target on Lava Therapeutics to $6 From $9, Maintains Buy Rating	23-08-23	MT
HC Wainwright Starts Lava Therapeutics at Buy With $9 Price Target	22-10-25	MT
SVB Securities Adjusts Price Target on Lava Therapeutics to $28 From $25, Keeps Outperform Rating	22-09-27	MT
JMP Securities Starts Lava Therapeutics at Market Outperform With $6 Price Target	22-09-15	MT
SVB Securities Adjusts LAVA Therapeutics' Price Target to $25 From $23, Keeps Outperform Rating	22-05-18	MT
SVB Leerink Adjusts Price Target on Lava Therapeutics to $20 from $24, Keeps Outperform Rating	21-11-16	MT
LAVA THERAPEUTICS B : SVB Leerink Adjusts Price Target on LAVA Therapeutics to $24 From $26, Maintains Outperform Rating	21-08-17	MT
LAVA THERAPEUTICS B : JP Morgan Starts Lava Therapeutics at Overweight with $22 Price Target	21-04-19	MT
LAVA THERAPEUTICS B : Jefferies Starts Lava Therapeutics at Buy with $23 Price Target	21-04-19	MT
LAVA THERAPEUTICS B : SVB Leerink Initiates LAVA Therapeutics at Outperform Rating With $26 Price Target	21-04-19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer